Prakhar Agrawal
Stock Analyst at Cantor Fitzgerald
(0.98)
# 3,144
Out of 4,786 analysts
51
Total ratings
24.44%
Success rate
-10.25%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Prakhar Agrawal
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ACRS Aclaris Therapeutics | Reiterates: Overweight | n/a | $1.53 | - | 1 | Mar 18, 2025 | |
| MTSR Metsera | Initiates: Overweight | n/a | $27.22 | - | 1 | Feb 25, 2025 | |
| TVTX Travere Therapeutics | Reiterates: Overweight | n/a | $17.92 | - | 1 | Feb 21, 2025 | |
| KROS Keros Therapeutics | Downgrades: Neutral | n/a | $10.19 | - | 3 | Jan 21, 2025 | |
| ORIC ORIC Pharmaceuticals | Reiterates: Overweight | n/a | $5.58 | - | 6 | Jan 14, 2025 | |
| ATYR aTyr Pharma | Initiates: Overweight | n/a | $3.02 | - | 1 | Jan 6, 2025 | |
| TLSI TriSalus Life Sciences | Initiates: Overweight | $10 | $5.52 | +81.16% | 1 | Dec 17, 2024 | |
| MDGL Madrigal Pharmaceuticals | Reiterates: Neutral | n/a | $331.23 | - | 4 | Nov 20, 2024 | |
| GPCR Structure Therapeutics | Reiterates: Overweight | $65 | $17.31 | +275.51% | 12 | Sep 23, 2024 | |
| MLTX MoonLake Immunotherapeutics | Reiterates: Overweight | n/a | $39.07 | - | 10 | Sep 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $40.48 | - | 5 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.22 | - | 2 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $24 | $39.43 | -39.13% | 2 | Apr 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $450 | $1.47 | +30,512.24% | 1 | Jul 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $14 | $0.39 | +3,468.70% | 1 | Mar 3, 2021 |
Aclaris Therapeutics
Mar 18, 2025
Reiterates: Overweight
Price Target: n/a
Current: $1.53
Upside: -
Metsera
Feb 25, 2025
Initiates: Overweight
Price Target: n/a
Current: $27.22
Upside: -
Travere Therapeutics
Feb 21, 2025
Reiterates: Overweight
Price Target: n/a
Current: $17.92
Upside: -
Keros Therapeutics
Jan 21, 2025
Downgrades: Neutral
Price Target: n/a
Current: $10.19
Upside: -
ORIC Pharmaceuticals
Jan 14, 2025
Reiterates: Overweight
Price Target: n/a
Current: $5.58
Upside: -
aTyr Pharma
Jan 6, 2025
Initiates: Overweight
Price Target: n/a
Current: $3.02
Upside: -
TriSalus Life Sciences
Dec 17, 2024
Initiates: Overweight
Price Target: $10
Current: $5.52
Upside: +81.16%
Madrigal Pharmaceuticals
Nov 20, 2024
Reiterates: Neutral
Price Target: n/a
Current: $331.23
Upside: -
Structure Therapeutics
Sep 23, 2024
Reiterates: Overweight
Price Target: $65
Current: $17.31
Upside: +275.51%
MoonLake Immunotherapeutics
Sep 23, 2024
Reiterates: Overweight
Price Target: n/a
Current: $39.07
Upside: -
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $40.48
Upside: -
Feb 20, 2024
Downgrades: Neutral
Price Target: n/a
Current: $1.22
Upside: -
Apr 17, 2023
Reiterates: Overweight
Price Target: $24
Current: $39.43
Upside: -39.13%
Jul 15, 2022
Assumes: Overweight
Price Target: $450
Current: $1.47
Upside: +30,512.24%
Mar 3, 2021
Initiates: Buy
Price Target: $14
Current: $0.39
Upside: +3,468.70%